Remedy Pharmaceuticals Announces Phase 2 Severe Stroke Study Results To Be Presented At Neurocritical Care Annual Meeting

PRESS RELEASE

REMEDY PHARMACEUTICALS ANNOUNCES PHASE 2 SEVERE STROKE STUDY RESULTS TO BE PRESENTED AT NEUROCRITICAL CARE ANNUAL MEETING

NEW YORK, September 29, 2015 — Remedy Pharmaceuticals, announced today that results from its severe stroke patient study, GAMES-RP, will be presented in an exclusive session at the Neurocritical Care Society Annual Meeting in Scottsdale, AZ on October 9, 2015. GAMES-RP is an exploratory Phase 2 randomized double blind, placebo-controlled, multi-center study of CIRARA™, a breakthrough drug for acute central nervous system conditions.
​
The co-principal investigators for the GAMES-RP trial, Dr. Kevin Sheth, MD, chief, Division of Neurocritical care and Emergency Neurology, chief of clinical research, Department of Neurology, Yale University, New Haven, Connecticut, and W. Taylor Kimberly, M.D., Ph.D., the Associate Director of the Massachusetts General Hospital Neuroscience Intensive Care Unit and an Assistant Professor of Neurology at Harvard Medical School, along with J. Marc Simard, M.D., Ph.D., Scientific Founder of CIRARA and Professor of Neurosurgery, Pathology and Physiology at the University of Maryland School of Medicine, will present the findings during a scheduled 75-minute session. Over 1,000 leaders in the neurocritical care field are expected to attend the meeting.

ABOUT CIRARA

CIRARA is a patented intravenous formulation that can be delivered bedside or even in an ambulance. CIRARA uses a proprietary, patented MPD™ dosing technology.

ABOUT REMEDY PHARMACEUTICALS

Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on bringing life saving treatment to millions of people affected by acute central nervous system conditions -- including stroke, traumatic brain injury, spinal cord injury, as well as other ischemic injuries and neurological disorders such as subarachnoid hemorrhage and intracerebral hemorrhage. For more information, please visit: www.remedypharmaceuticals.com

Contact: Sven Jacobson
212-586-2226 x 225
sven@remedypharmaceuticals.com